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Aim: To evaluate the efficacy of glycopyrrolate oral solution (1 mg/5 mL) in managing problem 
drooling associated with cerebral palsy and other neurologic conditions.
Method: Thirty-eight patients aged 3–23 years weighing at least 27 lb (12.2 kg) with 
severe drooling (clothing damp 5–7 days/week) were randomized to glycopyrrolate (n = 20), 
0.02–0.1 mg/kg three times a day, or matching placebo (n = 18). Primary efficacy endpoint 
was responder rate, defined as percentage showing $3-point change on the modified Teacher’s 
Drooling Scale (mTDS).
Results: Responder rate was significantly higher for the glycopyrrolate (14/19; 73.7%) than for 
the placebo (3/17; 17.6%) group (P = 0.0011), with improvements starting 2 weeks after treatment 
initiation. Mean improvements in mTDS at week 8 were significantly greater in the glycopyrrolate 
than in the placebo group (3.94 ± 1.95 vs 0.71 ± 2.14 points; P , 0.0001). In addition, 84% of 
physicians and 100% of parents/caregivers regarded glycopyrrolate as worthwhile compared with 
41% and 56%, respectively, for placebo (P # 0.014). Most frequently reported treatment-emergent 
adverse events (glycopyrrolate vs placebo) were dry mouth, constipation, and vomiting.
Interpretation: Children aged 3–16 years with problem drooling due to neurologic conditions 
showed a significantly better response, as assessed by mTDS, to glycopyrrolate than to placebo.
ClinicalTrials.gov identifier: NCT00425087.
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What this paper adds
•	 In a randomized, placebo-controlled, Phase III clinical trial, glycopyrrolate oral 
solution (1 mg/5 mL) was found to be significantly superior to placebo in controlling 
problem drooling in children aged 3–16 years with problem drooling associated 
with neurologic conditions.
•	 Significantly greater percentages of physicians and parents/caregivers of patients 
in the glycopyrrolate oral solution group regarded treatment as worthwhile.
•	 Glycopyrrolate oral solution was generally well tolerated.
Introduction
Sialorrhea (drooling or excessive salivation) is an unintentional loss of saliva from the 
mouth. Although normal in infants, drooling usually stops when at 15–18 months of 
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age and is considered pathologic if present after age 4 years. 
The most common cause of sialorrhea is neuromuscular 
dysfunction; other causes are hypersecretion and sensory or 
anatomic dysfunction, eg, failure of lip closure or infrequent 
swallowing.1 In children with cerebral palsy and other neuro-
muscular conditions, drooling may be due to hypersalivation 
and/or oral motor dysfunction.2,3
The prevalence of moderate-to-severe sialorrhea in devel-
opmentally disabled individuals is estimated at 10%–37%.4–6 
Among children with cerebral palsy who attended special 
schools, the incidence was 58% (93 of 160 children), 33% 
of whom drooled severely.7 In a survey of parents of 1437 
children with cerebral palsy, 34% reported that drooling was 
an occasional problem, and an additional 16% found it to be 
a frequent problem, requiring daily changes of clothing.8
Complications of sialorrhea can be both physical and 
psychological and can have a negative impact on quality 
of life. Drooling can result in perioral chapping, irritation, 
and maceration, with secondary infection of the facial skin, 
dehydration due to chronic loss of fluids, and increased risk of 
silent saliva aspiration that can result in recurrent respiratory 
infections.9 Moreover, drooling increases wetness, clothing 
odor, and social embarrassment; lowers self-esteem; and 
  limits vocational opportunities.9 In the school setting,   children 
may be unable to share books or computer electronics,1 and 
levels of care and dependency may increase.10,11
Treatment options explored to control drooling in chil-
dren and adults include behavioral approaches, such as 
prompts to swallow or wipe12 or preventing individuals from 
  putting their fingers or objects into their mouths;13 surgery 
to decrease salivary flow,14 intraglandular injection of botu-
linum toxin type A,15,16 and anticholinergic agents such as 
benztropine, glycopyrrolate, trihexyphenidyl hydrochloride, 
and scopolamine patches.11,17
Glycopyrrolate (glycopyrronium bromide) is a synthetic 
quaternary ammonium anticholinergic agent11 with poor 
penetration of the blood–brain barrier, as shown by the direct 
measurement of radiolabeled glycopyrrolate in anesthetized 
dogs,18 thus reducing the ability of glycopyrrolate to cause 
central nervous system effects.19,20 Glycopyrrolate was 
first approved for clinical use in 1961. Currently approved 
indications in the US include adjunctive treatment of peptic 
ulcer disease in adults and as a preoperative or intraoperative 
medication in adults and children 2 years of age and older. It is 
used preoperatively to inhibit salivation and excessive secretions 
of the respiratory tract. Additionally, glycopyrrolate has been 
used for children with tracheostomies who have difficulty 
managing secretions. Off-label use of commercially available 
oral glycopyrrolate tablets has been shown to decrease 
drooling in children with cerebral palsy.8,9,21,22 However, 
these tablets require compounding to dose pediatric patients, 
and the highly variable pharmacokinetics of glycopyrrolate 
resulted in wide-ranging doses and adverse events, leading to 
treatment discontinuation.9 These findings have encouraged the 
development of a novel liquid formulation of glycopyrrolate, 
oral glycopyrrolate solution (1 mg/5 mL), providing more 
accurate pediatric dosing and titration. We have performed a 
randomized, double-blind, placebo-controlled Phase III trial 
to assess the efficacy and safety of this new formulation in 
managing problem drooling associated with cerebral palsy and 
other neurologic conditions in children. We also assessed the 
effectiveness of a training manual, designed to help educate 
patients and caregivers to identify adverse events (AEs) 
secondary to treatment with oral glycopyrrolate solution and 
to manage dosing regimens.
Material and methods
Participants
Male and female patients weighing at least 27 lb (12.2 kg) and 
previously diagnosed with cerebral palsy, mental retardation, 
or another neurologic condition associated with problem 
drooling were eligible for enrollment. Problem drooling 
was defined as drooling in the absence of treatment such 
that clothing became damp approximately 5–7 days/week. 
Patients with oral feeding problems or who used a tube for 
feeding were included. Female patients of childbearing 
potential were required to have a negative pregnancy test at 
the pretreatment visit and were counseled on the importance 
of not becoming pregnant.
Patients were excluded if their extent of drooling was 
wetness of the lips and chin but their clothes did not become 
damp on most days; if they had used glycopyrrolate liquid 
within approximately 24 hours of baseline; if they had used 
any anticholinergic or cholinergic medications   prohibited 
by the protocol within three plasma half-lives of that 
medication prior to baseline; or if they had medical   conditions 
contraindicating anticholinergic therapy or treatment with 
the study medication.
The study was conducted according to Good Clinical 
Practice guidelines and in full compliance with the World 
Assembly Declaration of Helsinki and its most recent 
amendments.
Interventions
The initial treatment dose was calculated based on body 
weight and assigned at the randomization visit. The initial 
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dose was 0.02 mg/kg three times a day, and was titrated 
according to schedule over a 4-week period to optimal 
response, with a maximum dose of 0.1 mg/kg or 3 mg, 
three times a day, whichever was less. Since high-fat foods 
reduce the oral bioavailability of glycopyrrolate oral solution 
administered shortly after a meal, we advised that the test 
liquid be administered at least 1 hour before or 2 hours after 
meals at 7–8 am, 1–2 pm, and 7–8 pm. Parents/caregivers 
were instructed on how to measure dose levels using an 
oral syringe and a dosing cup; for patients with gastrostomy 
feeding tubes, Luer lock syringes were provided. The FDA-
required training manual, which included the dose titration 
schedule, was provided to each parent/caregiver; it was also 
used to facilitate the recognition of AEs and the need for 
dose adjustments.
Outcomes
Primary outcome measures
The primary efficacy endpoint was responder rate, based on 
change in degree (severity and frequency) of drooling, as 
measured by parents/caregivers, using the modified 9-point 
Teacher’s Drooling Scale (mTDS), which was assessed at 
baseline and at weeks 2, 4, 6, and 8. The mTDS is scored from 
1 (dry, never drools) to 9 (profuse: clothing, hands, tray, and 
objects become wet; frequently). At the request of the FDA, 
the primary endpoint was changed to “dichotomized mTDS,” 
which defined responders as those having an increase $3 
units on the mTDS.
Secondary outcome measures
Secondary outcome measures included daily mean   parent/
caregiver mTDS scores at weeks 2, 4, and 6; AUC   analysis of 
all mTDS evaluations from screening to week 8; proportion 
of patients who discontinued treatment due to lack of 
  efficacy; global assessments by the parent/caregiver, by 
patients deemed cognitively capable by the investigator, and 
by physicians, performed at week 8 or at the last visit, using a 
5-point scale, ranging from 1 (strongly agree) to 5 (strongly 
disagree) in response to the statement “This is a worthwhile 
treatment”; assessments using a modified Behavioral and 
Medical Rating Scale (mBMRS);23 and tabulation and 
description of all AEs.
The mBMRS is a scale that measures the frequency of 
28 prespecified symptoms at each study visit using a scale 
of 1 through 4, where 1 represents not at all; 2, just a bit; 3, 
quite a bit; and 4, very much. This scale can be used by 
parents/caregivers to identify possible AE-related behav-
iors and physiologic effects in patients taking study drug. 
The mBMRS score at each visit was the average of non-
missing responses to the 28 symptoms; the score was cal-
culated only if none of these symptoms was missing. The 
behavioral and symptom subscales of the mBMRS were the 
means of the first 12 and last 16 symptoms, respectively. 
A positive change reflected improvement, and a negative 
change reflected worsening.
We also assessed the effectiveness of the training manual, 
“Glycopyrrolate Liquid for the Treatment of Problem Drooling 
Associated with Cerebral Palsy or Other Neurologic Conditions 
in Children: For Parents and Caregivers of Patients,” to educate 
parents and caregivers about drooling. The most frequent AEs 
and the beneficial effects of glycopyrrolate oral solution in 
these patients were also identified.
Safety was evaluated by physical examination, 12-lead 
ECG, clinical laboratory test results, and urinalysis, assessed 
at baseline and at week 8 or study discontinuation.
Randomization
Prospective patients were screened within 3 weeks of 
  dosing. Those receiving anti-sialogenic compounds or other 
medications with anticholinergic or cholinergic activity 
underwent a washout phase prior to baseline, beginning 
8 days before randomization. Doses of study medication were 
titrated over a 4-week period to optimal response, after which 
patients remained on that dose for an additional 4 weeks.
Patients were randomized 1:1 to oral glycopyrrolate oral 
solution or matching placebo oral solution (similar in color 
and taste) three times a day. During the first 4 weeks, doses 
were titrated weekly to the optimal tolerated response for 
each study participant, but not exceeding 1.5–3.0 mg per 
dose based on weight, with the optimal tolerated dose reached 
by week 4. Five dose levels (0.02 mg/kg three times a day, 
0.04 mg/kg three times a day, 0.06 mg/kg three times a day, 
0.08 mg/kg three times a day, and 0.1 mg/kg three times 
a day) were evaluated. After the optimal dose level was 
reached, patients continued to receive the same medication 
and dose, for a total of 8 weeks.
Blinding
As patients receiving placebo would be expected to continue 
drooling chronically, caregivers of patients in this group were 
specifically encouraged to keep patients in the study until at 
least the end of the 4-week titration period.
Statistical methods
Data from all centers were combined. All percentages 
were based on the total number of patients in each group 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
17
glycopyrrolate oral solution for drooling in childrenTherapeutics and Clinical Risk Management 2012:8
(two-sided P values). Patients who dropped out before the 
end of the study had the lowest rank carried forward. All 
statistical hypothesis tests used a type I (alpha) error of 
0.05. All statistical calculations were performed using SAS® 
software (v 9.1.3; SAS Institute, Cary, NC).
According to the statistical analysis plan, all patients who 
received at least one dose of study drug were to be included 
in the safety population, and all randomized patients were to 
be included in the intent-to-treat (ITT) analysis of efficacy. In 
practice, two patients were randomized to treatment before 
the protocol was amended to set an upper age limit, and these 
patients no longer met the inclusion criteria. Thus, efficacy 
was assessed in a modified ITT (mITT) population, defined 
as all randomized patients who were within the age range of 
the final, amended protocol and received at least one dose 
of study medication. Consequently, these two patients were 
included in the analyses of safety but not of efficacy.
Results
This study was conducted between November 2002 and 
April 2007. The study duration, from first patient screened 
to last patient completed, was approximately 4.5 years. 
A temporary hold was placed on enrollment from November 
2005 to September 2006 (10 months) pending receipt of 
orphan drug designation for glycopyrrolate liquid, which 
was granted on June 9, 2006, for the indication “treatment of 
pathologic (chronic moderate to severe) drooling in pediatric 
patients” by the US Food and Drug Administration Office of 
Orphan Products Development.
Forty-seven patients were screened at ten US clinical 
trial sites, and 38 patients aged 3–23 years were random-
ized to treatment with glycopyrrolate oral solution or pla-
cebo (Figure 1). Of them, 36 patients were 3–16 years of 
age and two were older. The mITT population included 19 
patients in the glycopyrrolate oral solution group and 17 in 
the placebo group. Their demographic and baseline clinical 
characteristics were similar (Table 1). Most patients had 
cerebral palsy, 16 (84.2%) in the glycopyrrolate oral solution 
group and 14 (82.4%) in the placebo group. In the glyco-
pyrrolate oral solution group, 14 patients each (87.5%) had   
spastic cerebral palsy and were quadriplegic; in the placebo 
group, 13 (92.9%) each had spastic cerebral palsy and were 
quadriplegic. In the glycopyrrolate oral solution group, 
ten patients (52.6%) had oral feeding problems and seven 
Assessed for eligibility (n = 47)
Randomized (n = 38)
Allocated to glycopyrrolate oral solution
(1 mg/5 mL) (n = 20)
Allocated to placebo (n = 18)
Excluded (n = 9)
    Did not meet inclusion criteria
Discontinued intervention (n = 2)
    Adverse event: 1 patient
    Patient/parent decision: 1 patient
Discontinued intervention (n = 2)
    Lack of efficacy: 1 patient
    Patient/parent decision: 1 patient
Analyzed for efficacy (n = 17)
Analyzed for safety (n = 18)
Analyzed for efficacy (n = 19)
Analyzed for safety (n = 20)
Enrollment
Allocation
Follow-up
Analysis*
Figure 1 CONSORT flow diagram.
Note: *Protocol was amended to set an upper age limit, which led to 1 fewer patient being included in the modified intent-to-treat (mITT) population for the efficacy analysis 
for both the glycopyrrolate oral solution (1 mg/5 mL) and placebo groups.
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(36.8%) used a tube for feeding; in the placebo group, eight 
(47.1%) had oral feeding problems and five (29.4%) used a 
tube for feeding. Eighteen patients (94.7%) in the glycopyr-
rolate oral solution and 15 (88.2%) in the placebo group 
were well-nourished.
Exposure to study drug
The mean daily dose of glycopyrrolate oral solution was 
0.15 mg/kg, with 13 patients (68.4%) having mean daily 
doses $0.1 mg/kg to #0.2 mg/kg. The mean length of 
drug exposure in this group was 55.4 days (89.5% for .50 
to #100 days); 17 of 19 (89.5%) completed the study, with 
ten reaching the highest dose level for baseline weight. Of the 
17 who completed the 4-week maintenance period, 13 missed 
at least one dose of study drug (estimated compliance: 
90%–100% for patients with up to 168 doses). Overall, the 
19 patients in the glycopyrrolate oral solution group required 
56 up-titrations and 11 down-titrations.
Within the placebo group, 15 of 17 patients (88.2%) 
completed the study, with 14 (82.3%) reaching the highest 
dose level for baseline weight. Of the 15 who completed the 
study, seven missed at least one dose of study drug (estimated 
compliance: 91%–100% for patients with up to 168 doses). 
Overall, the 17 patients in the placebo group required 67 
up-titrations and three down-titrations.
Efficacy
At week 8, 14 of 19 patients (73.7%) in the glycopyrrolate 
oral solution group and three of 17 (17.6%) in the placebo 
group exhibited at least a 3-point improvement in mTDS 
score (P = 0.0011, Fisher’s exact test; Figure 2A). A beneficial 
effect of glycopyrrolate oral solution was observed as early 
as 2 weeks after treatment initiation (52.6%; P = 0.0007), 
with the proportion of responders increasing continuously 
through week 8 (Figure 2B). Mean improvements in mTDS 
score at week 8 were 3.94 points (SD: 1.95, 95% confidence 
interval [CI]: 2.97–4.91, median: 4.30 points) in the glyco-
pyrrolate oral solution group and 0.71 points (SD: 2.14, 95% 
CI: –0.43–1.84, median: 0.25 points) in the placebo group 
(P , 0.0001).
Statistically significant group differences were observed 
for both the investigator and parent/caregiver global assess-
ments of study medication. For patients in the glycopyrrolate 
oral solution group, 84.2% of investigators and 100% of 
parent/caregivers agreed that the treatment was worthwhile, 
compared with 41.2% of investigators (P = 0.0140; Fisher’s 
exact test) and 56.3% of parent/caregivers (P = 0.0017; 
Fisher’s exact test) of patients in the placebo group.
Safety
All 20 patients treated with glycopyrrolate oral solution 
and 15 of 18 (83.3%) who received placebo had at least 
one treatment-emergent AE (TEAE), including 15 (75%) 
and seven (39%), respectively, who had TEAEs considered 
by the investigator to be related to treatment. Four patients 
(20%) in the glycopyrrolate oral solution group, but none 
in the placebo group, had at least one severe TEAE. One 
patient (5.0%) in the glycopyrrolate oral solution group 
experienced a serious AE, generalized tonic-clonic seizure 
activity followed by generalized convulsions, 8 days after the 
last dose of study drug, which was not considered related to 
study drug; no placebo patient had a serious AE. One patient 
in the glycopyrrolate oral solution group (5.0%) and one in 
the placebo group (5.6%) discontinued treatment because of a 
TEAE. The most common adverse reactions were dry mouth, 
vomiting, constipation, and nasal congestion (Table 2).
Table 1 Demographic and baseline clinical characteristics
Glycopyrrolate oral  
solution (1 mg/5 mL)  
(n = 19)
Placebo  
(n = 17)
Age, years 
  Mean (SD) 
  Range 
  $3 to #11 
  $12 to #18
 
10.2 (3.8) 
4–16 
12 (63.2%) 
7 (36.8%)
 
8.7 (4.0) 
3–16 
12 (70.6%) 
5 (29.4%)
Sex 
  Male 
  Female
 
13 (68.4%) 
6 (31.6%)
 
9 (52.9%) 
8 (47.1%)
Race 
  White 
  Black or African-American 
  Other
 
16 (84.2%) 
2 (10.5%) 
1 (5.3%)
 
10 (58.8%) 
7 (41.2%) 
0
Ethnicity 
  Hispanic or Latino 
  Not Hispanic or Latino
 
3 (15.8%) 
16 (84.2%)
 
6 (35.3%) 
11 (64.7%)
Mental retardation 
  Present
 
19 (100%)
 
17 (100%)
Speech impairment 
  Present
 
19 (100.0%)
 
17 (100.0%)
Oral feeding problems 
  Present 
  Absent
 
10 (52.6%) 
9 (47.4%)
 
8 (47.1%) 
9 (52.9%)
Uses tube for feeding 
  Yes 
  No
 
7 (36.8%) 
12 (63.2%)
 
8 (47.1%) 
9 (52.9%)
Residence of patient 
  With parent 
  With foster parent/guardian
 
17 (89.5%) 
2 (10.5%)
 
16 (94.1%) 
1 (5.9%)
History of glycopyrrolate use 
  Yes 
  No
 
3 (15.8%) 
16 (84.2%)
 
3 (17.6%) 
14 (82.4%)
Abbreviation: SD, standard deviation.
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The mBMRS analysis was based on available scores from 
only five patients in the glycopyrrolate oral solution group 
and four in the placebo group. Their mean increases from 
baseline were 0.20 and 0.13, respectively, and their mean 
increases in behavioral subscale score were 0.44 and 0.23, 
respectively. Of all AEs reported in the study, 39.9% were 
identified by the parent/caregiver, and 4.5% by the investiga-
tor using the mBMRS.
Discussion
We have shown here that the responder rate to glycopyrrolate 
oral solution was significantly greater than the responder rate 
to placebo in the management of severe to moderate drooling 
associated with cerebral palsy and other neurologic conditions 
in children aged 3–16 years, and that   glycopyrrolate oral 
solution was well-tolerated in these children. More than 
85% of patients in this study had cerebral palsy, classified 
as spastic and quadriplegic; were developmentally disabled; 
had impaired speech; resided at home with a parent or foster 
parent/guardian; and had no history of oral glycopyrrolate 
use. In addition, both investigators and parents/caregivers 
assessed glycopyrrolate oral solution as superior to placebo 
in controlling drooling.
In this trial, the maximum recommended dosage of glyco-
pyrrolate oral solution was 0.1 mg/kg or 3 mg TID, whichever 
was lower, according to the dose titration schedule. The liquid 
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Figure 2 (A) Percent responders in each group, defined as >3-point change on the mTDS; (B) mean mTDS scores (+2 SEMs) over time for the mITT population.
Abbreviations: mITT, modified intent-to-treat; mTDS, modified Teacher’s Drooling Scale; SEM, standard error of the mean.
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formulation provides a premixed uniform solution for 
accurate, individualized pediatric dosing and titration based 
on patient response to treatment and permits more precise 
weight-based dosing than is possible with oral tablets.24 Once 
an initial dose has been selected, clinical signs can be used 
to titrate the dose for each child over several weeks until 
control of drooling is deemed satisfactory. Caregiver use of 
the training manual and continued discussion with the child’s 
physician can assist in facilitating dose adjustments.
The mBMRS, which measures the frequency of 
pre  specified symptoms at each study visit,23 was used 
by parents/caregivers to identify possible AE-related 
behaviors and physiologic effects in patients taking 
glycopyrrolate oral solution. A positive change reflected 
improvement, and a negative change reflected worsening. 
The most common AEs observed with glycopyrrolate 
oral solution are related to its mechanism of action as 
an anticholinergic agent. Glycopyrrolate oral solution is 
contraindicated in patients with conditions that preclude 
anticholinergic therapy, including glaucoma, paralytic 
ileus, unstable cardiovascular status in acute hemorrhage, 
severe ulcerative colitis, toxic megacolon, complications 
of ulcerative colitis, and myasthenia gravis; in patients 
taking solid oral potassium chloride; and in those with 
constipation or intestinal pseudo-obstruction.
Four prior studies have assessed glycopyrrolate for the 
treatment of sialorrhea in children with cerebral palsy and 
other neurologic conditions; two were open-label,21,22 one a 
retrospective review,8 and one a prospective, randomized, 
double-blind, dose-ranging trial.9 In the randomized trial, 39 
children aged $4 years were assigned to one of two dosage 
regimens based on weight. Children ,30 kg were started 
at 0.6 mg, with weekly increases to 1.2 mg, 1.8 mg, and 
2.4 mg, whereas children .30 kg were started at 1.2 mg, 
with weekly increases to 1.8 mg, 2.4 mg, and 3.0 mg. In 
that trial, commercially available glycopyrrolate tablets were 
ground up and placed into gelatin capsules. If the child could 
not swallow the capsule, the parent was allowed to take the 
capsule apart and place its powdered contents into the child’s 
food. In that study, almost all children demonstrated a marked 
improvement in drooling. AEs also increasd as the dose 
increased, with 20% of the children stopping glycopyrrolate 
due to behavioral problems, constipation, excessive oral 
dryness, or urinary retention.
In children with cerebral palsy, neurodevelopmental 
delays may disturb lip closure, intraoral tongue suction, 
and swallowing, resulting in sialorrhea due to disturbed 
coordination of tongue mobility, not to hypersalivation.24 
A recent meta-analysis of surgical management of drooling 
found most evidence to be of low quality and heterogeneous, 
with varying levels of success.14 Use of botulinum toxin 
is not likely to supplant surgical treatment due to its 
temporary effects, but it may be useful in empirically 
selected candidates for durable surgical treatment of the 
major salivary glands.14
Although the number of patients in this trial was small, 
most clinical studies of orphan drugs do not include large 
numbers of subjects.25
Conclusion
Treatment with glycopyrrolate oral solution significantly 
improves problem drooling in children aged 3–16 years with 
cerebral palsy and other neurologic conditions. Using the 
mTDS as the primary outcome measure, children treated with 
individually optimized doses of glycopyrrolate oral solution 
showed a significantly better clinical response rate than did 
children who received placebo.
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